Back to All

US$1m contract with leading life sciences company for data feed from the DXRX platform

14 December, 2021

Featured

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that it has secured a five year subscription contract with a top five global life sciences company, a global leader in diagnostics, to deliver customised data insights via the DXRX platform. The total contract value is in excess  of $1m spread across five years and subject to milestones in year 1 and year 3. This contract demonstrates the demand for customised real-world data to support sales and marketing initiatives for leading life science companies, the applicability of the Company’s offering to businesses outside of its core pharma  customer base, and supports the move towards enhanced subscription-based revenues, a key strategy for the Company going forward. 

The contract will see Diaceutics deliver real-world data and insights on the demand for biomarkers customised to the client’s needs across a number of diseases. This information will help the customer to identify important biomarker adoption trends and gaps which can support the commercialisation of new  and existing diagnostics. The data will be supplied from DXRX, the world’s first diagnostic commercialisation platform for Precision Medicine, which uses machine learning to integrate output of real-world, real time diagnostic testing data  from a global network of laboratories. 

Peter Keeling, CEO and Founder of Diaceutics PLC, commented:  “This multi-year deal demonstrates the confidence which one of the acknowledged global leaders in  diagnostics has in the quality of our Deductive Diagnostic Pathways, and the strength of the DXRX  platform. “This agreement represents another step towards our recurring, high margin and scalable multi-year  subscription revenue targets and reinforces our belief in the opportunity for the DXRX platform, to serve multiple stakeholders across healthcare industry unlock the promise of Precision Medicine.”

Enquiries: 

Diaceutics PLC Philip White, Chief Financial Officer Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600 Ben Maddison, Stewart Wallace, Nick Adams 

Alma PR Tel: +44(0)20 3405 0205  Caroline Forde, Kieran Breheny, Matthew Young [email protected]

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny